The estimated Net Worth of Kirsten Flowers is at least $1.1 Milione dollars as of 27 January 2023. Ms Flowers owns over 1,906 units of Kura Oncology Inc stock worth over $409,627 and over the last 5 years she sold KURA stock worth over $26,474. In addition, she makes $661,252 as Chief Commercial Officer at Kura Oncology Inc.
Ms has made over 1 trades of the Kura Oncology Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she sold 1,906 units of KURA stock worth $26,474 on 27 January 2023.
The largest trade she's ever made was selling 1,906 units of Kura Oncology Inc stock on 27 January 2023 worth over $26,474. On average, Ms trades about 238 units every 0 days since 2020. As of 27 January 2023 she still owns at least 20,605 units of Kura Oncology Inc stock.
You can see the complete history of Ms Flowers stock trades at the bottom of the page.
Kirsten Flowers is the Chief Commercial Officer at Kura Oncology Inc.
As the Chief Commercial Officer of Kura Oncology Inc, the total compensation of Ms Flowers at Kura Oncology Inc is $661,252. There are 8 executives at Kura Oncology Inc getting paid more, with Kathleen Ford having the highest compensation of $3,485,030.
Ms Flowers is 46, she's been the Chief Commercial Officer of Kura Oncology Inc since . There are 20 older and 1 younger executives at Kura Oncology Inc. The oldest executive at Kura Oncology Inc is Kathleen Ford, 74, who is the Chief Operating Officer.
Kirsten's mailing address filed with the SEC is C/O PMV PHARMACEUTICALS, INC., 1 RESEARCH WAY, PRINCETON, NJ, 08540.
Over the last 6 years, insiders at Kura Oncology Inc have traded over $16,903,587 worth of Kura Oncology Inc stock and bought 50,000 units worth $575,000 . The most active insiders traders include Faheem Hasnain, Troy Edward Wilson e Mary T Szela. On average, Kura Oncology Inc executives and independent directors trade stock every 63 days with the average trade being worth of $626,260. The most recent stock trade was executed by Teresa Brophy Bair on 20 May 2024, trading 2,615 units of KURA stock currently worth $57,922.
at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.
Kura Oncology Inc executives and other stock owners filed with the SEC include: